A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies
Phase: PHASE2
Conditions: Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

 
 
 
 
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy 
(BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate 
Cancer Progressing on Combined Androgen Ablative Therapies. 
 
 
NCT number: NCT02090114 
 
 
 
 
Protocol Version 11 
July 2, 2020